Abbreviation	Meaning/Phrase
ACE	angiotensin-converting enzyme
ACHD	adult congenital heart disease
ACS	acute coronary syndrome
AF	atrial fibrillation
AFL	atrial flutter
AHRE	atrial high-rate episodes
ANS	autonomic nervous system
AP	accessory pathway
APT	antiplatelet therapy
ARB	angiotensin receptor blocker
AT	atrial tachycardia
AVNA	atrioventricular nodal ablation
BiVP	biventricular pacing
BMI	body mass index
BP	blood pressure
bpm	beats per minute
BTK	Bruton’s tyrosine kinase
CABG	coronary artery bypass graft surgery
CAD	coronary artery disease
CCD	chronic coronary disease
CHADS2	congestive heart failure, hypertension, age >75 years, diabetes mellitus, stroke/transient ischemia attack/thromboembolism
CHA2DS2-VASc	congestive heart failure, hypertension, age ≥75 years (doubled), diabetes mellitus, prior stroke or transient ischemic attack or thromboembolism (doubled), vascular disease, age 65 to 74 years, sex category
CHD	congenital heart disease
CHF	congestive heart failure
CKD	chronic kidney disease
COPD	chronic obstructive pulmonary disease
COR	Class of Recommendation
CrCl	creatinine clearance
CRT	cardiac resynchronization therapy
CTI	cavotricuspid isthmus
CVD	cardiovascular disease
DAT	dual antithrombotic therapy
DOAC	direct oral anticoagulant
ECG	electrocardiogram
EF	ejection fraction
eGFR	estimated glomerular filtration rate
FDA	U.S. Food and Drug Administration
GDMT	guideline-directed management and therapy
HF	heart failure
HFpEF	heart failure with preserved ejection fraction
HFrEF	heart failure with reduced ejection fraction
HR	hazard ratio
ICD	implantable cardioverter-defibrillator
ICH	intracranial hemorrhage
LA	left atrium
LAA	left atrial appendage
LAAO	left atrial appendage occlusion
LOE	Level of Evidence
LRFM	lifestyle risk factor modification
LV	left ventricular
LVEF	left ventricular ejection fraction
MI	myocardial infarction
MRA	mineralocorticoid receptor antagonist
NYHA	New York Heart Association
OAC	oral anticoagulant
PAC	premature atrial contraction
PAD	peripheral artery disease
PCI	percutaneous coronary intervention
PCC	prothrombin complex concentrate
PE	pulmonary embolism
PH	pulmonary hypertension
PHPVD	pulmonary hypertension with pulmonary vascular disease
PITP	pill-in-the-pocket
pLAAO	percutaneous left atrial appendage occlusion
PV	pulmonary veins
PVI	pulmonary vein isolation
QOL	quality of life
RAAS	renin-angiotensin-aldosterone system
RCT	randomized controlled trial
RV	right ventricular
RVP	right ventricular pacing
SDB	sleep-disordered breathing
SDOH	social determinants of health
SDM	shared decision-making
S-LAAO	surgical removal of the left atrial appendage occlusion
SVT	supraventricular tachycardia
TEE	transesophageal echocardiogram
TIA	transient ischemic attack
UREG	underrepresented racial and ethnic groups
VF	ventricular fibrillation
VHD	valvular heart disease
VKA	vitamin K antagonist
VT	ventricular tachycardia
WPW	Wolff-Parkinson-White